

Alexandre Puissant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4309930/publications.pdf>

Version: 2024-02-01

79
papers

4,025
citations

117625

34
h-index

118850

62
g-index

83
all docs

83
docs citations

83
times ranked

10597
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. <i>Cancer Discovery</i> , 2013, 3, 308-323. | 9.4 | 549 |
| 2 | Resveratrol Promotes Autophagic Cell Death in Chronic Myelogenous Leukemia Cells via JNK-Mediated p62/SQSTM1 Expression and AMPK Activation. <i>Cancer Research</i> , 2010, 70, 1042-1052. | 0.9 | 335 |
| 3 | Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. <i>Cell Death and Disease</i> , 2011, 2, e199-e199. | 6.3 | 250 |
| 4 | InÂVivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling. <i>Cancer Cell</i> , 2013, 24, 45-58. | 16.8 | 144 |
| 5 | When autophagy meets cancer through p62/SQSTM1. <i>American Journal of Cancer Research</i> , 2012, 2, 397-413. | 1.4 | 139 |
| 6 | The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. <i>Leukemia</i> , 2012, 26, 1195-1202. | 7.2 | 138 |
| 7 | Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death. <i>Cell Death and Differentiation</i> , 2013, 20, 611-619. | 11.2 | 137 |
| 8 | SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 226-242. | 16.8 | 126 |
| 9 | Autophagy, a key mechanism of oncogenesis and resistance in leukemia. <i>Blood</i> , 2017, 129, 547-552. | 1.4 | 121 |
| 10 | Targeting MTHFD2 in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2016, 213, 1285-1306. | 8.5 | 118 |
| 11 | Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. <i>Oncogene</i> , 2016, 35, 5119-5131. | 5.9 | 96 |
| 12 | Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line. <i>Autophagy</i> , 2009, 5, 1092-1098. | 9.1 | 92 |
| 13 | The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 301-313. | 30.7 | 79 |
| 14 | Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death. <i>PLoS ONE</i> , 2009, 4, e7889. | 2.5 | 79 |
| 15 | BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients. <i>Oncotarget</i> , 2012, 3, 490-501. | 1.8 | 75 |
| 16 | Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1924-1933. | 4.1 | 71 |
| 17 | Targeting autophagy to fight hematopoietic malignancies. <i>Cell Cycle</i> , 2010, 9, 3470-3478. | 2.6 | 70 |
| 18 | Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2018, 10, . | 12.4 | 69 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | AMPK- and p62/SQSTM1-dependent autophagy mediate Resveratrol-induced cell death in chronic myelogenous leukemia. <i>Autophagy</i> , 2010, 6, 655-657. | 9.1 | 63 |
| 20 | SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. <i>Oncogene</i> , 2011, 30, 4887-4900. | 5.9 | 60 |
| 21 | Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. <i>FASEB Journal</i> , 2008, 22, 1894-1904. | 0.5 | 59 |
| 22 | Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC. <i>Cancer Research</i> , 2010, 70, 9659-9670. | 0.9 | 56 |
| 23 | Ultrasound-assisted one-pot synthesis of anti-CML nucleosides featuring 1,2,3-triazole nucleobase under iron-copper catalysis. <i>Ultrasonics Sonochemistry</i> , 2012, 19, 1132-1138. | 8.2 | 56 |
| 24 | Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties. <i>Cell Cycle</i> , 2013, 12, 2183-2193. | 2.6 | 52 |
| 25 | In Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1208-1218. | 0.7 | 51 |
| 26 | Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer. <i>Nature Genetics</i> , 2020, 52, 408-417. | 21.4 | 47 |
| 27 | CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. <i>Blood</i> , 2020, 136, 387-400. | 1.4 | 46 |
| 28 | Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. <i>Oncogene</i> , 2007, 26, 2445-2458. | 5.9 | 45 |
| 29 | The anti-apoptotic Bcl-B protein inhibits BECN1-dependent autophagic cell death. <i>Autophagy</i> , 2012, 8, 637-649. | 9.1 | 45 |
| 30 | SYK regulates mTOR signaling in AML. <i>Leukemia</i> , 2013, 27, 2118-2128. | 7.2 | 44 |
| 31 | Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells. <i>Leukemia</i> , 2010, 24, 115-124. | 7.2 | 43 |
| 32 | The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. <i>Oncotarget</i> , 2014, 5, 6252-6266. | 1.8 | 43 |
| 33 | Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. <i>Cell Cycle</i> , 2011, 10, 2339-2343. | 2.6 | 37 |
| 34 | The p53/p21 ^{Cip1} /Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 219-232. | 3.3 | 36 |
| 35 | Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. <i>Journal of Molecular Cell Biology</i> , 2012, 4, 207-220. | 3.3 | 32 |
| 36 | Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. <i>Cell Death and Differentiation</i> , 2011, 18, 109-121. | 11.2 | 31 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib. <i>Oncotarget</i> , 2012, 3, 1557-1565. | 1.8 | 30 |
| 38 | Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. <i>Science Translational Medicine</i> , 2021, 13, . | 12.4 | 29 |
| 39 | Dual Role of Sp3 Transcription Factor as an Inducer of Apoptosis and a Marker of Tumour Aggressiveness. <i>PLoS ONE</i> , 2009, 4, e4478. | 2.5 | 29 |
| 40 | Mechanism of action of the multikinase inhibitor Foretinib. <i>Cell Cycle</i> , 2011, 10, 4138-4148. | 2.6 | 28 |
| 41 | BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. <i>Journal of Experimental Medicine</i> , 2016, 213, 1705-1722. | 8.5 | 24 |
| 42 | Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1585-1595. | 7.2 | 24 |
| 43 | Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells. <i>Leukemia</i> , 2009, 23, 1500-1506. | 7.2 | 23 |
| 44 | Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. <i>Leukemia</i> , 2022, 36, 348-360. | 7.2 | 23 |
| 45 | Drug Resistance in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6091. | 4.1 | 21 |
| 46 | Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 25575-25587. | 1.8 | 20 |
| 47 | The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production. <i>Cell Death and Differentiation</i> , 2012, 19, 1769-1778. | 11.2 | 19 |
| 48 | Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. <i>Oncotarget</i> , 2017, 8, 52026-52044. | 1.8 | 19 |
| 49 | Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1154-1171. | 6.1 | 18 |
| 50 | Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells. <i>Leukemia</i> , 2010, 24, 1099-1101. | 7.2 | 17 |
| 51 | MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. <i>Blood</i> , 2014, 123, 734-742. | 1.4 | 16 |
| 52 | Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439. | 9.4 | 16 |
| 53 | Structure elucidation of the new citharoxazole from the Mediterranean deep-sea sponge <i>Latrunculia (Biannulata) citharistae</i> . <i>Magnetic Resonance in Chemistry</i> , 2011, 49, 533-536. | 1.9 | 13 |
| 54 | The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. <i>Cancer Discovery</i> , 2020, 10, 1894-1911. | 9.4 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML. <i>Leukemia</i> , 2019, 33, 800-804. | 7.2 | 10 |
| 56 | BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias. <i>Leukemia Research</i> , 2019, 87, 106269. | 0.8 | 9 |
| 57 | Endothelial cells: major players in acute myeloid leukaemia. <i>Blood Reviews</i> , 2022, 54, 100932. | 5.7 | 9 |
| 58 | Screening of ETO2-GLIS2-induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemia. <i>Science Advances</i> , 2022, 8, eabg9455. | 10.3 | 9 |
| 59 | P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. <i>Nature Cancer</i> , 2022, 3, 837-851. | 13.2 | 9 |
| 60 | HER2 Signaling Hijacks the Creatine Shuttle to Fuel Breast Cancer Cell Growth. <i>Cell Metabolism</i> , 2018, 28, 805-807. | 16.2 | 8 |
| 61 | Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1856-1860. | 7.2 | 7 |
| 62 | A multiparametric niche-like drug screening platform in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, . | 6.2 | 6 |
| 63 | A new posttranslational regulation of REDD1/DDIT4 through cleavage by caspase 3 modifies its cellular function. <i>Cell Death and Disease</i> , 2014, 5, e1349-e1349. | 6.3 | 5 |
| 64 | Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 12-13. | 1.4 | 4 |
| 65 | BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients. <i>Blood</i> , 2012, 120, 701-701. | 1.4 | 2 |
| 66 | Targeting MTHFD2 in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 443-443. | 1.4 | 2 |
| 67 | The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. <i>Blood</i> , 2019, 134, 877-877. | 1.4 | 1 |
| 68 | Induction of Autophagic Cell Death Circumvents Azacitidine-Resistance In Myelodysplastic Syndrome-Derived Cell Lines. <i>Blood</i> , 2010, 116, 1817-1817. | 1.4 | 1 |
| 69 | Targeting Folate Metabolism In Acute Myelogenous Leukemia. <i>Blood</i> , 2013, 122, 3798-3798. | 1.4 | 1 |
| 70 | Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 21-21. | 1.4 | 1 |
| 71 | Autophagy and blood diseases. <i>Hematologie</i> , 2015, 21, 107-116. | 0.0 | 0 |
| 72 | In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling. <i>Blood</i> , 2011, 118, 758-758. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Involvement of autophagy in cellular development and differentiation. <i>Hematologie</i> , 2015, 21, 212-220. | 0.0 | 0 |
| 74 | Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML. <i>Blood</i> , 2015, 126, 2472-2472. | 1.4 | 0 |
| 75 | Identification of CKMT1B As a New Target in EVI1-Positive AML. <i>Blood</i> , 2015, 126, 3674-3674. | 1.4 | 0 |
| 76 | Implication of the Anti-Apoptotic Protein Bcl-B (BCL2L10) in the Pathogenesis of Multiple Myeloma. <i>Blood</i> , 2015, 126, 2958-2958. | 1.4 | 0 |
| 77 | Targeting MTHFD2 in acute myeloid leukemia. <i>Journal of Cell Biology</i> , 2016, 214, 21410IA135. | 5.2 | 0 |
| 78 | Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 523-523. | 1.4 | 0 |
| 79 | Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia. <i>Blood</i> , 2017, 130, 880-880. | 1.4 | 0 |